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Chronic obstructive pulmonary disease (COPD) is recognised as 
among the top five causes of death globally, and rates are declining more 
slowly than for other chronic non-communicable diseases. More than 
90% of these deaths occur in low- and middle-income countries. [1-4] 
COPD is a progressive disease, and in adults lung function, measured 
as forced expiratory volume in 1 second (FEV1), declines more rapidly 
than is associated with normal ageing, particularly in continuing 
smokers.[5] However, disease progression is variable, some patients 
experiencing rapid and others slow deterioration.[6] In many adults 
with chronic airflow obstruction (CAO), lung function may have 
been low since earlier decades owing to sub-normal lung development 
resulting from respiratory infections, malnutrition, factors associated 
with poverty, parental smoking and other exposure to atmospheric 
pollutants, and even adverse intrauterine factors. Longitudinal surveys 
of COPD progression suggest that the rate of lung function loss is 
greater in individuals with lesser degrees of airflow obstruction.[7-9]
In South Africa (SA), a Burden of Obstructive Lung Disease 
(BOLD) study performed in two low- to middle-income suburbs 
of Cape Town in 2005 confirmed a very high prevalence of CAO 
(Global initiative for Obstructive Lung Disease (GOLD) stage ≥2) in 
both men and women aged ≥40 years; 22.2% of men and 16.7% of 
women had evidence of CAO, compared with a global average of 
10.1% in similar studies performed in countries with a range of 
socioeconomic status.[10,11] In the SA cohort, the most significant 
risk factors for CAO were tobacco (cigarette) smoking, a past 
history of pulmonary tuberculosis (PTB), occupational exposures 
and a history of asthma. Further analyses of global experience 
have confirmed this association of previous PTB and COPD, but 
it does not alone account for the high prevalence of CAO in SA.[12] 
Faced with this heavy burden of CAO in SA, it is important to 
better understand its causes, clinical manifestations and course, 
and the prospects for prevention and treatment.
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Background. A community-based prevalence survey performed in two suburbs in Cape Town, South Africa (SA), in 2005, using the 
international Burden of Obstructive Lung Disease (BOLD) method, confirmed a prevalence of chronic airflow obstruction (CAO) in 23.1% 
of adults aged >40 years.
Objectives. To study the clinical course and prognosis over 5 years of patients with CAO identified in the 2005 survey.
Methods. Patients with CAO in 2005 were invited to participate. Standard BOLD and modified questionnaires were completed. Spirometry 
was performed using spirometers of the same make as in 2005.
Results. Of 196 eligible participants from BOLD 2005, 45 (23.0%) had died, 8 from respiratory causes, 10 from cardiovascular causes and 6 
from other known causes, while in 21 cases the cause of death was not known. On multivariate analysis, only age and Global initiative for 
Obstructive Lung Disease (GOLD) stage 4 disease at baseline were significantly associated with death. Of the 151 survivors, 11 (5.6% of the 
original cohort) were unavailable and 33 (16.8%) declined or had medical exclusions. One hundred and seven survivors were enrolled in 
the follow-up study (54.6%, median age 63.1 years, 45.8% males). Post-bronchodilator spirometry performed in 106 participants failed to 
confirm CAO, defined as a forced expiratory volume in 1 second (FEV1)/forced vital capacity (FVC) ratio of <0.7, in 16 participants (15.1%), 
but CAO was present in 90. The median decline in FEV1 was 28.9 mL/year (interquartile range –54.8 - 0.0) and was similar between GOLD 
stages. The median total decline in FVC was 75 mL, and was significantly greater in GOLD stage 1 (–350 mL) than in stages 2 or 3 (–80  mL 
and +140 mL, respectively; p<0.01). Fifty-eight participants with CAO in 2005 (64.4%) remained in the same GOLD stage, while 21 (23.3%) 
deteriorated and 11 (12.2%) improved by ≥1 stage. Only one-third were receiving any treatment for chronic obstructive pulmonary disease 
(COPD).
Conclusions. The prevalence, morbidity and mortality of CAO and COPD in SA are high and the level of appropriate treatment is very low, 
pointing to underdiagnosis and inadequate provision of and access to effective treatments and preventive strategies for this priority chronic 
non-communicable disease.
S Afr Med J 2018;108(2):138-143. DOI:10.7196/SAMJ.2018.v108i2.12688
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Objectives
To assess the clinical outcome, including mortality, and current 
management of participants 5 years after they were identified as 
having CAO in the BOLD 2005 study.
Methods
The BOLD 2005 study was performed in Ravensmead and Uitsig, 
two low- to middle-income suburbs in Cape Town, SA, in adults 
>40 years of age, using a population-based single-stage cluster sample 
and the BOLD method, comprising standardised questionnaires and 
spirometry.[11] The population in the follow-up study, performed 
5 years later, comprised participants identified in the BOLD study as 
having CAO, defined as an FEV1/forced vital capacity (FVC) ratio of 
<0.7. The term CAO rather than COPD was used in the follow-up 
study in recognition of the fact that in a minority of cases conditions 
other than smoking-related COPD, e.g. asthma, bronchiectasis or 
chronic destructive changes of previous PTB, might account for airflow 
obstruction.
At follow-up, attempts were made by community workers to establish 
the vital status of all participants either by telephonic consultation or 
repeated door-to-door visits, and all participants who were traced were 
invited to participate in the current study. Where participants were no 
longer present at the residence, information was obtained from other 
local community members (e.g. neighbours or relatives), and repeated 
attempts were made to contact and enrol these participants.
Participants who provided informed written consent attended the 
University of Cape Town Lung Institute, where questionnaires were 
completed and spirometry was performed. Questionnaires included 
the standard BOLD questionnaires, the modified Medical Research 
Council Dyspnoea Score (mMRC) and the St George’s Respiratory 
Question naire (SGRQ). Owing to poor literacy in a significant 
proportion of partici pants, questionnaires were administered by a 
trained investigator. The range of the SGRQ score is 0 - 100, a 
higher score indicating more severe disease and a total score of >25 
considered as the threshold for starting treatment.[3] HIV testing 
was performed after counselling and obtaining of written consent. 
Spirometry was performed by trained respiratory technologists in 
accordance with American Thoracic Society/European Respiratory 
Society guidelines. Spirometers of the same make (EasyOne ndd, ndd 
Medical Technologies Inc., USA) as had been used in the 2005 BOLD 
survey were used in the follow-up study. Spirometers were calibrated 
daily using a 3 L syringe,[12,13] and spirometry was performed before 
and 45 minutes after the inhalation of both 100 µg of salbutamol and 
80 µg of ipratropium bromide, administered via a pressurised metered 
dose inhaler. Bronchodilator reversibility was defined as an increase 
in FEV1 of >200 mL and 12% of baseline value. The GOLD severity 
scale based on FEV1 and expressed as the percentage of predicted FEV1 
is as follows: stage 1 (FEV1 ≥80% of predicted), stage  2 (50 - 79%), 
stage  3 (30 - 49%), and stage 4 (<30%).  Predicted values for FEV1 
were calculated using the National Health and Nutrition Examination 
Survey (NHANES) III reference equations.[3,14]
Participants were excluded if they could not be traced, refused 
participation, had a condition that contraindicated spirometry or 
administration of a bronchodilator, or had an additional medical 
condition likely to affect spirometry. For participants who were reported 
to have died, two registers (City of Cape Town and South African 
Medical Research Council databases) were scrutinised for information 
on the cause of death.
Approval to conduct the study was obtained from the ethics committees 
of the University of Cape Town (ref. no. 441/2009), Stellenbosch 
University (ref. no. N/09/11/328) and the City of Cape Town (ref. 
no. 10165). Data were double-entered into the database, and statistical 
analysis using appropriate tests for parametric and non-parametric data 
was performed using Stata version 12.1 (StataCorp, USA).
Results
The BOLD study of 2005 sampled 847 adults aged >40 years. CAO 
was confirmed in 196 (23.1%), 34 (4.0%) in GOLD stage 1, 109 
(12.9%) in stage 2, 48 (5.7%) in stage 3 and 5 (0.6%) in stage 4. 
At 5-year follow-up, 45 (23.0%) of the participants with airflow 
limitation had died. Of the participants who were alive at follow-up, 
11 (5.6%) had moved away from the survey area and could not be 
traced, 19 (9.7%) declined participation, and 14 (7.1%) were excluded 
from participation on medical grounds (5 with dementia, 3 with 
malignancy and 6 for miscellaneous medical reasons) (Fig. 1).
One hundred and seven patients (54.6% of the original participants 
with COPD with airflow limitation) were included in the subsequent 
analysis, but one further subject was unable to perform spirometry. All 
the participants identified themselves as ‘coloured’ (mixed race),[15] and 
none was HIV-positive. Forty-nine (45.8%) were men, their median age 
was 63.1 years (range 46.4 - 82.7), and 13 (12.2%) had never smoked 
(Table 1). The mean number of pack-years in current smokers (n=60) 
was similar to that of ex-smokers (n=34), 24.8 and 26.9 pack-years, 
respectively. Thirty-nine participants (36.5%) reported a history of 
previous PTB. Twenty (52.3%) reported that their first episode of PTB 
had occurred before the age of 40 years (range 6 - 77) and 13 (33.3%) 
reported more than one episode. Ten participants (9.3%) reported that 
they had received treatment for active tuberculosis (TB) during the 
5 years between the two studies; in 7 this was a first episode, and in 3 
it represented a recurrence. On clinical review, a diagnosis of asthma 
was made in 18 subjects (17.0%), of whom 15 had CAO.
The median SGRQ total score at follow-up was 33.4 (interquartile 
range (IQR) 14.1 - 54.1). This was not measured in the original study. 
The mMRC dyspnoea score was ≥2 (breathlessness when hurrying on 
a level or up a slight hill) in 59.8% of participants at follow-up, with 
54.2% of participants reporting worsening over the 5-year period 
and 13.1% improvement. Sixty-three participants (58.9%) reported 
a chronic cough, compared with 48 (44.9%) in the initial study. 
The majority of the participants (n=68, 63.6%) reported no use of 
medications for their lung condition. Less than one-third reported 
use of short-acting beta-2-agonists, and only four (3.7%) used a long-
acting bronchodilator (Table 1).
Mortality
Of the 45 deaths, 8 (17.8%) were due to respiratory causes, 10 
(22.2%) were due to cardiovascular disease and 6 (13.3%) were 
from miscellaneous causes; the cause of death was unknown 
in 21 parti cipants (46.7% of deaths) (Fig. 1). The majority of the 
deaths (57.7%) occurred in participants with mild/moderate COPD 
(i.e. GOLD stages 1 or 2) in the original study. The mean (standard 
deviation (SD)) age of participants who died was 63.3 (11.2) years, 
and 24 (53.3%) of the deaths were in men. Death occurred in 6 of 
34 participants (17.7%) who had been designated as in GOLD stage 1 
in 2005, 20 of 109 (18.3%) in stage 2, 15 of 48 (31.3%) in stage 3 and 
4 of 5 (80.0%) in stage 4. On multivariate analysis, only age (p=0.003) 
and GOLD stage 4 COPD (p=0.006) were significantly associated 
with mortality – gender, pack-years of smoking, years of schooling 
and a history of previous PTB were not (Table 2).
Spirometry
In the 106 participants who underwent repeat spirometry, the median 
post-bronchodilator FEV1 was 1.51 L (IQR 1.12 - 2.13), compared 
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with 1.64 L (IQR 1.28 - 2.27) in the baseline study (p<0.0001). 
There was, however, no difference in the median FEV1 reported as 
percentage of predicted between the two studies (62.7% and 63.8%, 
respectively; p=0.316). The corresponding median FVC values were 
2.66 L (IQR 2.09 - 3.45) and 2.77 L (IQR 2.22 - 3.54), respectively 
(p=0.0419), and 82.6% and 82.3% of the predicted value, respectively 
(p=0.773) (Table 3 and Fig. 2). Bronchodilator reversibility was found 
in 34 participants (32.1%).
In 16 of 106 participants (15.1%), post-bronchodilator spirometry did 
not confirm airflow obstruction at the follow-up visit (i.e. FEV1/FVC 
≥0.7). These and a further 11 participants had a post-bronchodilator 
FEV1/FVC ratio above the predicted lower limit of normal, i.e. were 
not obstructed using the lower limit of normal definition of airflow 
obstruction. Fifty-nine of the 106 participants (55.6%), including 
nine who no longer had airflow obstruction, had an FVC <80% of the 
predicted value, i.e. a restricted lung function pattern.
The comparison of GOLD staging at baseline and follow-up is 
shown in Table 4. Of the 90 participants with airflow obstruction in 
2010, 58 (64.4%) remained in the same GOLD stage, 21 (23.3%) had 
deteriorated and 11 (12.2%) had improved by one GOLD stage.
The median decline in post-bronchodilator FEV1 was 28.9 mL per 
year (IQR –54.8 - 0.0), but expressed as a percentage of predicted 
FEV1 (corrected for age) was not significant (change = –1.1, SD 11.0). 
No difference in the rate of FEV1 decline by GOLD stage in 2005 was 
observed.
The median total decline in FVC was –75 ml (IQR –420 - +200), 
and similarly was not significantly different when expressed as a 
percentage of predicted FVC (change = 2.48, IQR –9.38 - +10.42). 
However, the decline in median FVC was significantly greater 
in participants with initial GOLD stage 1 (–350 mL, IQR –520 - 
–190) compared with GOLD stage 2 (–80 mL, IQR –390 - +190) 
or GOLD stage 3 (+140 mL, IQR –160 - +270) (p<0.01). Similar 
significant differences were observed in median decline when FVC 
was expressed as a percentage of predicted between the same groups 
(–8.5%, +2.1% and +8.0%; p=0.01).
The median FEV1/FVC ratio declined by –2.5% (SD 9.76; p=0.005) 
(Table 3).
In participants reporting previous PTB (n=39), the median decline 
in FEV1 was 34.3 mL/year (IQR –63.6 - +3.6), which was not 
significantly different from those without previous PTB (–22.8 mL/
year, IQR –52.9 - –4.1; p=0.549). The 10 participants who contracted 
TB between the studies showed a median FEV1 decline of –47.0 mL/
year (IQR –78.0 - –21.2) compared with –26.7 mL/year (IQR –51.8 - 
0.0) for the remainder of the participants (p=0.210).
The median FVC decline was less in the 39 participants with a 
history of PTB than in those without (+22.8 mL/year, IQR –50.7  - 
+55.8 v. –22.2 mL/year, IQR –92.4 - +24.0; p=0.021) but not 
when expressed as percentage of predicted FVC (p=0.191). The 
median rate of decline in FVC in the 10 participants reporting 
Identied with COPD 
in 2005 BOLD study,
N=196
Enrolled,
n=107 (54.6%)
(1 unable to 
perform spirometry)
Died, n=45 (23.0%)
Respiratory, n=8
Cardiovascular, n=10
Cancer, n=3
Other cause, n=3
Unknown, n=21
Moved, n=11 (5.5%)
Declined, n=19 (9.7%)
Excluded, n=14 (7.1%)
Dementia, n=5
Malignancy, n=3
Miscellaneous medical reasons, n=6
Fig. 1. Follow-up, outcomes and enrolment of participants. (COPD = chronic 
obstructive pulmonary disease; BOLD = Burden of Obstructive Lung Disease.)
Table 1. Characteristics of participants enrolled in the 
follow-up study (N=107)
Male, n (%) 49 (45.8)
Age (years), median (IQR) 63.1 (55.2 - 69.8)
Smoking status, n (%)
Never smoked 13 (12.2)
Current smoker 60 (56.1)
Ex-smoker 34 (31.8)
Comorbidity, n (%)
Hypertension 52 (48.6)
Heart disease 15 (14.0)
High cholesterol 10 (9.3)
Diabetes 13 (12.1)
Previous cancer 2 (1.9)
Previous PTB 39 (36.5)
Diagnosis of asthma 18 (17.0)
No comorbidity 34 (31.8)
Post-bronchodilator lung function (N=106)
FEV1 (L), mean (SD) 1.63 (0.66)
FEV1 (% pred.), mean (SD) 62.7 (18.9)
FVC (L), mean (SD) 2.86 (0.98)
FVC (% pred.), mean (SD) 82.6 (15.4)
FEV1/FVC (%), mean (SD) 57.5 (14.0) 
No longer obstructed, n (%)* 16 (15.1)
Participants using respiratory medication, n (%) 39 (36.5)
Medications used, n (%)
Short-acting beta-2-agonist 32 (29.9)
Short-acting antimuscarinic 10 (9.4)
Long-acting beta-2-agonist 4 (3.7)
Long-acting antimuscarinic 0
Inhaled corticosteroid 18 (16.8)
Theophylline 10 (9.4)
Participants not receiving respiratory 
medication, n (%)
68 (63.6)
SD = standard deviation; IQR = interquartile range; PTB = pulmonary tuberculosis;  
FEV1 = forced expiratory volume in 1 second; FVC = forced vital capacity; % pred. = percentage of predicted.
*Obstruction defined as post-bronchodilator FEV1/FVC <0.7.
Table 2. Multivariate analysis of risk factors for mortality
Variable OR p-value 95% CI
Age 1.05 0.003 1.02 - 1.09
Gender: females (males 
were reference)
0.64 0.256 0.29 - 1.38
GOLD stage
1 Ref Ref Ref
2 1.11 0.845 0.38 - 3.29
3 2.47 0.140 0.74 - 8.23
4 29.16 0.006 2.61 - 325.22
Pack-years of smoking 1.01 0.332 0.99 - 1.02
Years of schooling 0.90 0.106 0.80 - 1.02
Previous PTB 1.92 0.137 0.81 - 4.58
OR = odds ratio; CI = confidence interval; GOLD = Global initiative for Obstructive Lung 
Disease; PTB = pulmonary tuberculosis.
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TB during the follow-up period was not 
statistically different to that of the remainder 
of the participants (–17.0 v. –11.9 mL/year; 
p=0.589).
Discussion
This 5-year follow-up study of participants 
identified with CAO in a population-based 
single-stage cluster sample from a low- to 
middle-income community in Cape Town, 
SA, although small and underpowered for 
definitive conclusions, is unique and provides 
useful insights into the nature, profile and 
outcome of the most prevalent forms of 
CAO seen in SA. These findings include 
the high mortality rate in this population, 
patterns of lung function decline, low use 
of respiratory medication, and a strong 
association with previous PTB. The findings 
must be viewed against the backdrop of 
an exceptionally high prevalence of CAO 
observed in the 2005 BOLD survey,[12] one 
of the highest reported globally. The role 
of PTB in this cohort has been studied in 
greater detail and reported elsewhere.[16,17] 
In addition, in this over-40 age group, ~15% 
of participants may be considered to have 
asthma with evidence of CAO at the time of 
the original survey. However, the majority 
of patients in the current study best fit the 
description of COPD, namely CAO with 
a significant history of smoking or similar 
exposure, with no or minimal evidence of 
post-PTB scarring on a chest radiograph and 
lung computed tomography scan.
Within the limitations of a small sample, 
the mortality rate over 5 years of almost 
25% for a COPD community-based cohort 
was unexpectedly high compared with the 
national age-specific death rate for this age 
group of ~20 - 35 deaths per 1 000 population 
over the same period.[18] More than half of 
these deaths occurred in patients previously 
diagnosed with only mild to moderate COPD, 
which may be at least partly explained by an 
excess of non-respiratory causes of death 
(e.g. cardiovascular deaths). Comorbid 
disease in COPD is well documented. In 
the Western Cape Province of SA it was 
found to occur in up to 88% of patients with 
chronic respiratory disease,[19] and it was also 
common in our participants who survived. 
Not unexpectedly, older age and very severe 
airflow obstruction were associated with 
mortality, but other factors responsible for 
this high mortality rate were not apparent, 
and are likely to be varied. However, the SA 
coloured population has previously been 
shown to have both a higher prevalence of 
smoking and a greater smoking-attributed 
proportion of deaths compared with the 
other population groups.[20] These and other 
Table 3. Comparison between post-bronchodilator FEV1, FVC and FEV1/FVC ratio between the BOLD and follow-up studies
BOLD study Follow-up study p-value
FEV1 (L), median (IQR) 1.64 (1.28 - 2.27) 1.51 (1.12 - 2.13) <0.0001(Wilcoxon)
FEV1 (% pred.), mean (SD) 63.8 (16.9) 62.7 (18.9) 0.316 (t-test for paired samples)
FVC (L), median (IQR) 2.77 (2.22 - 3.54) 2.66 (2.09 - 3.45) 0.0419 (Wilcoxon)
FVC (% pred.), median (IQR) 82.3 (69.1 - 92.1) 82.6 (71.8 - 94.2) 0.773 (Wilcoxon)
FEV1/FVC (%), median (IQR) 60.0 (55.8 - 67.2) 57.5 (46.1 - 66.2) 0.0047 (Wilcoxon)
FEV1 = forced expiratory volume in 1 second; FVC = forced vital capacity; BOLD = Burden of Obstructive Lung Disease; SD = standard deviation; % pred. = percentage of predicted value;  IQR = interquartile range; Wilcoxon = Wilcoxon signed-rank test.
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Fig. 2. FEV1 and FVC as percentage of predicted at BOLD and follow-up studies, according to GOLD 
(severity) staging at initial study. (FEV1 = forced expiratory volume in 1 second; FVC = forced vital capacity; 
BOLD = Burden of Obstructive Lung Disease; GOLD = Global initiative for Obstructive Lung Disease.)
Table 4. Comparison of GOLD stage between the BOLD and follow-up studies
GOLD stage at 
BOLD study
Not obstructed,   
n (%)
GOLD stage at follow-up study, n (%) 
1 2 3 4 Total, N
1 6 (35.3) 6 (35.3) 5 (29.4) 0 0 17
2 9 (13.8) 6 (9.2) 37 (56.9) 12 (18.5) 1 (1.5) 65
3 1 (4.3) 1 (4.3) 3 (13.0) 15 (65.2) 3 (13.0) 23
4 0 0 0 1 (100) 0 1
Total 16 (15.1) 13 (12.2) 45 (42.5) 28 (26.4) 4 (3.7) 106
Percentages = % of 2005 GOLD stage.
Cells with no blue tint demonstrate no interval change in GOLD stage.
BOLD = Burden of Obstructive Lung Disease; GOLD = Global initiative for Obstructive Lung Disease.
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reasons for the high mortality rate in our subjects with CAO need to 
be further investigated.
In our study, the overall lung function decline measured as FEV1 
and FVC followed age-related predictions, which implies a stable 
trajectory.[6] However, given the high mortality in our study, this might 
be influenced by a ‘healthy survivor’ effect, i.e. the death of more rapid 
decliners. The pattern of decline of lung function between GOLD 
stages was variable, however, a finding described in other studies.[7,21] 
The overall decline in FVC was age-appropriate, but was more rapid 
in the mild and moderate GOLD stages than in participants with more 
severe impairment (p<0.01). This more rapid lung function decline in 
early or less severe COPD is consistent with recent findings reported 
in large epidemiological studies, although at odds with the traditional 
lung function trajectories proposed by Fletcher and Peto.[5]
A further important finding in our study relates to the limitation 
of spirometry-based population surveys, namely the definitions and 
cut-offs that define chronic airflow limitation. Fifteen percent of our 
participants identified with CAO in the 2005 study no longer satisfied 
the criteria for CAO at follow-up. Possible reasons include the limited 
reproducibility of spirometry (3.5% for calibration),[13] natural intra-
subject variation of the measures over time, intercurrent events 
such as recent respiratory infections, and the presence of asthma. 
Seventeen percent of the current population were found to have 
asthma, and significant improvement of FEV1 after dual rapid-acting 
bronchodilator use was observed in 32.1% of the population tested, 
a common finding in both patients with asthma and those with 
COPD. Since we did not include participants who were unobstructed 
in 2005 in the follow-up study, we cannot confirm how many might 
have changed to an obstructed category. However, random variation 
around the cut-off for FEV1/FVC of 0.7 is well described.[22] An 
additional reason for the reversal of the FEV1/FVC from obstructed 
to non-obstructed is the unexpectedly higher decline in FVC in 
participants with milder CAO. Lastly, some participants may have 
improved either spontaneously, owing to removal from exposures 
(e.g. smoking cessation), or from use of medication. The significance 
of the change in FVC during follow-up lies in the fact that low vital 
capacity has been shown to be correlated with poverty and is a better 
predictor of mortality in COPD than airflow obstruction (percentage 
of predicted FEV1).[23]
A finding of concern for public health and policy-makers is the 
very low level of treatment reported in participants with symptomatic 
and severe COPD. The median SGRQ total score (33.4) reflects high 
levels of dyspnoea and chronic cough among participants. The current 
recommendation is that patients with scores of ≥25 warrant treatment 
for CAO.[3] Additionally, 30.2% of participants were in GOLD stages 3 
(severe) or 4 (very severe), yet only 3.7% reported use of a long-acting 
bronchodilator (LABA) as recommended in guidelines. LABAs and 
inhaled corticosteroids separately and in combination are available 
for prescription by specialist pulmonologists in the SA state sector, 
but access to specialised care is limited, denying patients effective 
treatment. Furthermore, long-acting antimuscarinics, the most 
widely used and most highly effective long-acting bronchodilator 
worldwide, are currently not available in state healthcare facilities 
in the Western Cape. The low levels of treatment may reflect both 
underdiagnosis in our population-based study and inadequate access 
to medications. These factors may account for much of the morbidity 
and poor outcomes of participants with CAO in our study. Our 
study highlights the plight of such patients and the need for access 
to effective treatments to be made available to patients with COPD.
The association between a history of previous PTB and CAO is 
described in many population-based studies, in which the pooled 
odds ratio (OR) of 3.05 for this association is estimated. [11,24] The 
reason for this association and causality remains unclear. [25] Significant 
observations in the current study related to this association are, first, 
that previous PTB was not associated with increased mortality 
(OR 1.92 (95% confidence interval 0.81 - 4.58)). Second, 9.3% 
of participants developed acute TB in the 5 years between the 
studies, yielding an annual incidence rate (1 860/100 000 popula-
tion) more than double that of the local community. This finding is 
in keeping with other studies, suggesting that COPD may predispose 
to TB infection and disease.[26,27] Third, more than half of those with 
previous PTB reported having their first episode of TB before the 
age of 40 years, lending weight to the proposal that TB may precede 
the development of CAO, and may be causative. However, this 
association could be bidirectional; CAO may be a consequence of TB, 
and a risk factor for the development of subsequent TB.
None of our enrolled participants were HIV-positive, which may 
appear unusual in SA. This may be explained by the age of the 
participant cohort, the relatively low prevalence of HIV infection in 
Cape Town, and the stable nature of the study community.
Study limitations
This study has a number of important limitations. First, its small 
size limits the strength of the findings. Second, the response rate was 
limited. Of the original cohort, 22.4% were alive but not enrolled. 
Third is the limited details on causes of deaths, unknown in almost 
half the cases. Fourth is lack of representivity of this low- to middle-
income community of people of mixed race to the SA population in 
general, which limits the application of the findings to other areas of 
the country.
Conclusions
This 5-year population-based follow-up study of patients with 
CAO, most of which may be defined as COPD, in a high-prevalence 
setting in SA confirms the seriousness of this condition and the 
gaps in its management. It confirms progression, particularly of 
FVC in patients with milder disease, which might be amenable to 
preventive measures (removal from harmful exposures, including 
smoking cessation) and effective treatment. It identifies the high 
symptom burden and mortality associated with this condition and 
the interaction with PTB, and points to the influence of very low 
levels of treatment currently being offered to patients with COPD. 
These results identify the urgent need for further studies of COPD 
in SA, examining its prevalence in other population groups and 
settings, the clinical burden and mortality, and gaps in diagnosis and 
treatment that need to be addressed as part of the current push to 
address non-communicable diseases.
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